Begin patient enrollment for refractory mesial temporal lobe epilepsy clinical trial
Delivered after the deadline (52 days after the deadline)
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 7 May 2024
- Due
- 30 Sep 2024
- Delivered
- 21 Nov 2024
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Patient enrollment in a Phase I/IIa clinical trial is expected to begin in third quarter of 2024.”
What we found
Evidence strength A What the grades mean
Patient enrollment observational phase occurred during Q3 2024, but first patient dosing occurred on 2024-11-21, after the Q3 deadline.
-
A uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial
“uniQure N.V. (NASDAQ: QURE) announced that the first patient has been dosed in the GenTLE Phase I/IIa clinical trial of AMT-260” ✓ confirmed on the page
-
B uniQure Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress
“The first patient has been enrolled into the observational phase of the Phase I/II clinical trial of AMT-260 for the treatment of mTLE.”
-
B uniQure Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress
“Due to the more restrictive inclusion criteria for these sentinel patients, enrollment has taken longer than expected.”
Checked 5 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Begin
- Deliverable
- MTLE clinical trial enrollment
- Where
- U.S.
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
- Depends on
- Regulatory
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Gemini (Google), re-read the evidence without being told the outcome and reached the same answer.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you uniQure N.V.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2024-QURE-001869 · Corrections policy